News & Updates

Testosterone does not induce recurrence in men after RP

Select men who underwent radical prostatectomy (RP) for organ-confined prostate cancer may safely use testosterone therapy, which does not seem to cause biochemical recurrence (BCR), according to a study.

Old age, OSA predict corporo-venocclusive dysfunction in men undergoing RP

Older age and the presence of obstructive sleep apnoea (OSA) are predictive of the presence of corporo-venocclusive dysfunction (CVOD) in men undergoing bilateral nerve-sparing radical prostatectomy (RP), reports a study.

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.

Nanoparticle-directed focal therapy feasible in men with prostate cancer

Use of nanoparticle-directed focal laser ablation results in the successful treatment of several patients with localized  (PCa), as confirmed by negative magnetic resonance (MR)/ultrasound (US) fusion biopsy of the treated lesion and a systematic biopsy.

Translating evidence into clinical care: Embracing the new era of testosterone replacement therapy

Social deprivation up risk of stricture recurrence after urethroplasty

Patients experiencing social deprivation are at greater risk for functional recurrence after anterior urethral stricture repair, suggests a study, noting the importance of preoperative counselling and postoperative surveillance.

Is epididymal cyst lesion linked to impaired semen parameters in men?

No association exists between semen parameters and epididymal cyst lesions (ECLs), which include both spermatoceles and epididymal cysts, among men presenting for fertility evaluation, a study has shown.

Tougher than tough: Corbridge launches Citrapos XR, new potassium citrate solution

[ Citrapos Panel Discussion ]